Announcements

Announcements

 

Paul G. Allen Frontiers Group [to 1 Feb 2020]
https://alleninstitute.org/what-we-do/frontiers-group/news-press/
News
No new digest content identified.

 

BMGF – Gates Foundation [to 1 Feb 2020]
http://www.gatesfoundation.org/Media-Center/Press-Releases
JANUARY 27, 2020
The Bill & Melinda Gates Medical Research Institute obtains license for continued development of M72/AS01E tuberculosis vaccine candidate from GSK
SEATTLE, January, 27, 2020 – Today, the Bill & Melinda Gates Medical Research Institute (Gates MRI) and the Bill & Melinda Gates Foundation (Gates Foundation) announced that GSK has licensed its M72/AS01E(3) tuberculosis disease (TB) vaccine candidate to the Gates MRI, paving the way for continued development and potential use of the vaccine candidate in countries with high TB burdens.

 

Bill & Melinda Gates Medical Research Institute [to 1 Feb 2020]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
News Release
Gates Medical Research Institute obtains license for continued development of M72/AS01E tuberculosis vaccine candidate from GSK
The Bill & Melinda Gates Medical Research Institute obtains license for continued development of M72/AS01E tuberculosis vaccine candidate from GSK
:: The M72/AS01E tuberculosis vaccine candidate demonstrated in a phase IIb trial the potential to reduce active pulmonary TB by half in adults with latent TB infection
:: Developing a new vaccine against TB is a global health priority to accelerate progress toward ending the TB epidemic and one of the United Nations Sustainable Development Goals.
:: The licensing agreement is a significant step forward to continue the development of the vaccine candidate for countries with high TB burdens.
27 January 2020 – Today, the Bill & Melinda Gates Medical Research Institute (Gates MRI) and the Bill & Melinda Gates Foundation (Gates Foundation) announced that GSK has licensed its M72/AS01E tuberculosis disease (TB) vaccine candidate to the Gates MRI, paving the way for continued development and potential use of the vaccine candidate in countries with high TB burdens. “Clinical trial results to date suggest that the M72/AS01E vaccine candidate could play a significant role in protecting vulnerable populations around the world from developing active TB. If that proves true, it could transform the fight against humanity’s deadliest infectious disease,” said Penny M. Heaton, M.D., CEO of Gates MRI. TB is the world’s deadliest infectious disease, with 10 million new cases and 1.5 million deaths in 2018 alone. The burden of disease is concentrated with over 97% of reported TB cases occurring in low- and middle-income countries…

 

CARB-X [to 1 Feb 2020]
https://carb-x.org/
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
No new digest content identified.

 

CEPI – Coalition for Epidemic Preparedness Innovations [to 1 Feb 2020]
http://cepi.net/
Latest news
CureVac and CEPI extend their Cooperation to Develop a Vaccine against Coronavirus nCoV-2019
CEPI funds CureVac’s development of a vaccine against coronavirus nCoV-2019. The aim of the partnering agreement is to rapidly advance a vaccine candidate into clinical testing.
31 Jan 2020

 

Clinton Health Access Initiative, Inc. (CHAI) [to 1 Feb 2020]
https://clintonhealthaccess.org/
News & Press Releases
No new digest content identified.

 

EDCTP [to 1 Feb 2020]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
30 January 2020
World NTD Day: the fight to end Neglected Tropical Diseases
EDCTP is a proud partner and supporter of this first World NTD Day, a call to action to end the burden of the neglected tropical diseases (NTDs). Pivotal in the renewed global focus on NTDs was the London Declaration of…

 

Emory Vaccine Center [to 1 Feb 2020]
http://www.vaccines.emory.edu/
No new digest content identified.

 

European Medicines Agency [to 1 Feb 2020]
http://www.ema.europa.eu/ema/
News & Press Releases
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 January 2020
CHMP, Last updated: 31/01/2020
…The Committee recommended granting a marketing authorisation for Vaxchora (Cholera vaccine (recombinant, live, oral)) for prophylaxis against cholera, a very serious disease caused by Vibrio cholerae, in adults and children….

 

European Vaccine Initiative [to 1 Feb 2020]
http://www.euvaccine.eu/news-events
No new digest content identified.

 

FDA [to 1 Feb 2020]
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
Press Announcements
January 29, 2020 – FDA launches mobile-friendly database with information on life-saving HIV drugs as part of ongoing mission to empower the public through increased access to information and data

January 28, 2020 – FDA Continues Strong Support of Innovation in Development of Gene Therapy Products

January 27, 2020 – FDA Announces Key Actions to Advance Development of Novel Coronavirus Medical Countermeasures

 

Fondation Merieux [to 1 Feb 2020]
http://www.fondation-merieux.org/
News, Events
Announcement
The Mérieux Foundation’s Emerging Pathogens Laboratory obtains accreditation according to European standard NF EN ISO/IEC 17025
January 23, 2020, Lyon (France)
This accreditation standard lays down the general requirements for competence, impartiality and consistency of laboratory activities. It promotes efficient and …

Project
The Haiti Ministry of Public Health and Population of Haiti launches its first National Health Research Policy
January 22, 2020, Port-au-Prince (Haiti)
Aware of the importance of research as an essential tool for improving people’s health, the Ministry of Public Health and …

 

Gavi [to 1 Feb 2020]
https://www.gavi.org/
News
Indonesia to protect four million children a year against pneumonia
Indonesia set to introduce pneumococcal conjugate vaccines (PCV) into routine immunisation programme
Barcelona, 29 January 2020

 

GHIT Fund [to 1 Feb 2020]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that No new digest content identified.

 

Global Fund [to 1 Feb 2020]
https://www.theglobalfund.org/en/news/
News & Stories
Updates
Technical Evaluation Reference Group: Thematic Review on Sustainability, Transition and Co-Financing Policy
31 January 2020

Funding Model
Funding Request Tracker for the 2020-2022 Funding Cycle
28 January 2020

 

Hilleman Laboratories [to 1 Feb 2020]
http://www.hillemanlabs.org/
PRESS RELEASE
Hilleman Board announces leadership changes
27th January 2020
The Board of Directors of Hilleman Laboratories today announced that Dr Davinder Gill will leave his current role as CEO of Hilleman Laboratories on 31 January 2020, after more than eight years at the company. Dr Gill is relocating to the United States where his family is based.
He will be replaced by Dr Raman Rao, who will assume the role as CEO on 1 February. Dr Rao has more than 22 years’ experience in research and development, manufacturing and commercialisation of vaccines for infectious diseases, and is joining from Takeda Vaccines where he was Vice President of Global Product Operations.
Dr Gill joined Hilleman in 2012 after two decades in the global pharmaceutical and biotechnology sector….

 

Human Vaccines Project [to 1 Feb 2020]
http://www.humanvaccinesproject.org/media/press-releases/
Press Releases
No new digest content identified.

 

IAVI [to 1 Feb 2020]
https://www.iavi.org/newsroom
January 29, 2020
IAVI Mourns the Passing of Maharaj Kishan Bhan, Respected Scientist, Leader, and Humanitarian
NEW YORK – January 29, 2020 – IAVI was deeply saddened to learn of the death of eminent scientist Maharaj Kishan Bhan, M.D., a longtime friend of IAVI. Dr. Bhan died on January 26, 2020, in New Delhi, India, at age 72…
… IAVI president and CEO Mark Feinberg, M.D., Ph.D., said, “Dr. Bhan was a friend, mentor, and trusted advisor who had an indelible effect on many lives. His contributions to public health reach far beyond the beneficial effects of his rotavirus vaccine. He was uniquely effective at getting things done, navigating complicated circumstances, and inspiring people to work together. Everyone who knew Dr. Bhan never doubted that he was focused solely on doing the right thing for people. The quality of his thinking and his quiet, humble demeanor made him a force for good in the world.”…

 

 

International Coalition of Medicines Regulatory Authorities [ICMRA]
http://www.icmra.info/drupal/en/news
Selected Statements, Press Releases, Research
No new digest content identified.

 

 

International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
News
No new digest content identified.

 

 

IFFIm
http://www.iffim.org/
No new digest content identified.

 

IFRC [to 1 Feb 2020]
http://media.ifrc.org/ifrc/news/press-releases/
Selected Press Releases, Announcements
Asia Pacific, Global
Red Cross scales up preparedness for global response as novel coronavirus declared an international health emergency
Geneva/Kuala Lumpur, 31 January 2020 – As the novel coronavirus (2019-nCoV) continues spreading beyond China, the International Federation of Red Cross and Red Crescent Societies (IFRC) is scaling up preparedness efforts to support people who are most vulnerable to the outbreak in Asia Pacific and beyond.
1 February 2020

 

IVAC [to 1 Feb 2020]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates
No new digest content identified.

 

IVI [to 1 Feb 2020]
http://www.ivi.int/
Selected IVI News & Announcements
How IVI is confronting schistosomiasis in Madagascar
[Undated]
…IVI is approaching schistosomiasis control in Madagascar through treatment, education, and prevention, including mass PZQ administration and “water, sanitation & hygiene” (WASH) activities, as well as accelerating a promising vaccine candidate, SchistoShield®, soon in a Phase I clinical study…

 

JEE Alliance [to 1 Feb 2020]
https://www.jeealliance.org/
Selected News and Events
No new digest content identified.

 

MSF/Médecins Sans Frontières [to 1 Feb 2020]
http://www.msf.org/
Latest [Selected Announcements]
Syria
Advancing frontlines, mass exodus and reduced access to hospitals in Idlib
Project Update 31 Jan 2020

Measles
Tackling a massive measles outbreak in DRC’s Kongo Central province
Project Update 31 Jan 2020

DRC Ebola outbreaks
Crisis update – January 2020
Crisis Update 31 Jan 2020

Central American Migration
Despite kidnapping and continued risks, migrants continue journey north through Mexico
Project Update 30 Jan 2020

Epidemics and pandemics
MSF update on 2019-nCoV coronavirus outbreak
Project Update 30 Jan 2020

Central American Migration
The devastating toll of ‘Remain in Mexico’ asylum policy one year later
Press Release 29 Jan 2020

 

National Vaccine Program Office – U.S. HHS [to 1 Feb 2020]
https://www.hhs.gov/vaccines/about/index.html
NVAC 2020 Meetings
February 13-14, 2020 NVAC Meeting
June 9-10, 2020 NVAC Meeting
September 23-24, 2020 Meeting (Virtual)

 

NIH [to 1 Feb 2020]
http://www.nih.gov/news-events/news-releases
Selected News Releases
First human trial of monoclonal antibody to prevent malaria opens
January 27, 2020 — NIH trial will test NIAID-developed antibody

 

PATH [to 1 Feb 2020]
https://www.path.org/media-center/
Selected Announcements
No new digest content identified.

 

Sabin Vaccine Institute [to 1 Feb 2020]
http://www.sabin.org/updates/pressreleases
Statements and Press Releases
No new digest content identified.

 

UNAIDS [to 1 Feb 2020]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
29 January 2020
#InSpiteOf campaign reached more than a million people [Eastern Europe/Central Asia]

27 January 2020
Key population-led organizations delivering health services in Bangkok

27 January 2020
Violence faced by key populations
Gains have been made against HIV-related stigma and discrimination, but discriminatory attitudes remain extremely high in far too many countries. Discrimination can manifest in criminal laws that give license to discrimination, aggressive law enforcement, harassment and violence, pushing key populations to the margins of society and denying them access to basic health and social services, including HIV services.
Surveys and studies across regions show that large percentages of key populations are victims of physical and sexual violence: among 36 countries with recently available data, more than half of sex workers in eight countries reported experiencing physical violence…

 

UNICEF [to 1 Feb 2020]
https://www.unicef.org/media/press-releases
Selected Statements, Press Releases, Reports
Statement
UNICEF Executive Director Henrietta Fore’s remarks at Fighting for Breath: The Global Forum on Childhood Pneumonia
As Delivered
29/01/2020

Press release
UNICEF ships 6 metric tons of supplies to support China’s response to Novel Coronavirus outbreak
Shipment includes masks and protective suits to help contain virus
29/01/2020

Press release
9 million children could die in a decade unless world acts on pneumonia, leading agencies warn
Malnutrition, air pollution and lack of access to vaccines and antibiotics among the drivers of preventable deaths from pneumonia—which last year killed a child every 39 seconds
28/01/2020

Press release
Nearly 5 million children will need humanitarian assistance in central Sahel this year as violence surges
Number is projected to rise as attacks against children increase in Burkina Faso, Mali and Niger
27/01/2020

Press release
European Investment Bank and UNICEF partner to help improve access to quality education and protect children from climate change
27/01/2020

 

Vaccination Acceptance Research Network (VARN) [to 1 Feb 2020]
https://vaccineacceptance.org/news.html#header1-2r
No new digest content identified.

 

Vaccine Confidence Project [to 1 Feb 2020]
http://www.vaccineconfidence.org/
No new digest content identified.

 

Vaccine Education Center – Children’s Hospital of Philadelphia [to 1 Feb 2020]
http://www.chop.edu/centers-programs/vaccine-education-center
No new digest content identified.

 

Wellcome Trust [to 1 Feb 2020]
https://wellcome.ac.uk/news
News | 31 January 2020
Wellcome pledges £10 million to tackle novel coronavirus epidemic
Wellcome is making a pledge of up to £10 million to accelerate research and support global efforts to tackle the ongoing novel coronavirus epidemic.

Opinion | 29 January 2020
What can funders do to encourage inclusive research leadership?
by Jack Harrington

Opinion | 28 January 2020
Race for new antibiotics: future success is hanging by a thread
by Tim Jinks

 

The Wistar Institute [to 1 Feb 2020]
https://www.wistar.org/news/press-releases
Press Releases
No new digest content identified.

 

World Organisation for Animal Health (OIE) [to 1 Feb 2020]
https://www.oie.int/en/for-the-media/press-releases/2020/
No new digest content identified.

 

 

::::::

 

ARM [Alliance for Regenerative Medicine] [to 1 Feb 2020]
https://alliancerm.org/press-releases/
Press Releases
The Alliance for Regenerative Medicine Outlines Recommendations on Enabling Cross-border and Regional Access to Advanced Therapy Medicinal Products (ATMPs) in Europe
BRUSSELS, BELGIUM – January 27, 2020

 

BIO [to 1 Feb 2020]
https://www.bio.org/press-releases
Press Releases
Survey shows only 15% of executives and 14% of biotech board members are people of color.
WASHINGTON DC., January 30, 2020 – The Biotechnology Innovation Organization (BIO) today released “Measuring Diversity in the Biotech Industry: Building an Inclusive Workforce,” the most comprehensive report on diversity and inclusion in the…

 

DCVMN – Developing Country Vaccine Manufacturers Network [to 1 Feb 2020]
http://www.dcvmn.org/
News
Advanced Pharmacovigilance workshop and WG meeting
16 March 2020 to 19 March 2020, Shanghai / China

 

IFPMA [to 1 Feb 2020]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications
IFPMA Statement on the G-FINDER report 2019
Published on: 30 January 2020
G-FINDER report: Investment in neglected disease R&D by multinational pharmaceutical companies grew by more than a quarter in 2018, reaching its highest-ever level

Geneva, 30 January 2020: IFPMA, the global R&D biopharmaceutical industry association, welcomes the 2019 G-FINDER report, which tracks public, private and philanthropic investment into product R&D for neglected diseases. The report shows the biopharmaceutical industry is now the second largest funder, after the USA’s National Institutes of Health (NIH) and before the Bill and Melinda Gates Foundation.

Private sector funding for neglected diseases, which predominantly affect the developing countries, rose sharply in 2018. The multinational pharmaceutical companies invested a total of $598m in neglected disease R&D in 2018 (up $132m, or a 28% increase). As products progressed through the pipeline, companies invested heavily in clinical development and post registration studies ($422m, 71%), with 20% ($118) of the funding dedicated to early-stage research.

It is also encouraging that the 2018 increase was distributed more evenly that in the past. Nearly half (43%) of the growth in multinational pharmaceutical companies investment went to diseases outside the “big three” (HIV/AIDS, malaria and TB).

While overall funding for the WHO neglected tropical diseases (NTDs)[1] has remained fairly flat over the last decade, industry investment has actually been one of the few positive stories in this area, with a steady growth over the course of the last twelve years, increasing five-fold since 2007…

 

PhRMA [to 1 Feb 2020]
http://www.phrma.org/
Selected Press Releases, Statements
No new digest content identified.